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1 
Serum D-dimer is a Promising Test for the Diagnosis of Periprosthetic Joint Infection and 1 
Timing of Reimplantation  2 
2 
ABSTRACT: 3 
Background: Despite the availability of battery of tests, the diagnosis of periprosthetic joint 4 
infection (PJI) continues to be challenging. Introduction of synovial biomarkers has improved 5 
the diagnosis, however, obtaining synovial fluid is invasive, occasionally impossible and carries 6 
the risk of introduction of infection into the joint. There is a desperate need for a serum marker 7 
of PJI.  Serum D-dimer is a widely available test that detects fibrinolytic activities that occurs 8 
during infection.  We hypothesized that patients with PJI may have a high level of circulating D-9 
dimer and that the presence of high levels of serum D-dimer may be a sign of persistent infection 10 
in patients awaiting reimplantation. 11 
Methods: This prospective study was initiated to enroll patients undergoing primary and revision 12 
arthroplasty. Our cohort consists of 245 patients undergoing primary arthroplasty (N=23), 13 
revision for aseptic failure (N=86), revision for PJI (N=57), patients undergoing reimplantation 14 
(N=29), and a group of patients with infection in a different site than the joint (N=50). PJI was 15 
defined using the Musculoskeletal Infection Society criteria. All patients in the study had serum 16 
D-dimer, erythrocyte sedimentation (ESR), and C-reactive protein (CRP) measured 17 
preoperatively.  18 
Results: The median D-dimer was statistically higher (p<0.0001) in PJI patients 19 
(1,100ng/mL,range:243-8,487ng/mL) compared to (299ng/mL,range:106-6,381ng/mL) in 20 
patients with aseptic failure. Using the Youden’s index, 850ng/mL was determined as the 21 
optimal threshold for serum D-dimer for diagnosis of PJI. Serum D-dimer outperformed both the 22 
ESR and the serum CRP with a sensitivity of 89% and a specificity of 93%. ESR and CRP had a 23 
sensitivity of 73% and 79% and a specificity of 78% and 80%, respectively. The sensitivity and 24 
3 
specificity of ESR and CRP combined was 84%(95%CI:76-90%) and 47%(95%CI:36-58%), 25 
respectively. 26 
Conclusion: It appears that the serum D-dimer is a promising marker for diagnosis of PJI. This 27 
test may also have a great utility for determining the optimal timing of reimplantation. This study 28 
demonstrates that serum D-dimer can be utilized as a screening test for PJI.  29 
Level of Evidence: Diagnostic Level II.   30 
4 
INTRODUCTION: 31 
Despite its immense impact on patients and society, the diagnosis of periprosthetic joint infection 32 
(PJI) remains imperfect and often very challenging1. Currently an absolute test for diagnosis of 33 
PJI does not exist, compelling the clinicians to rely on a combination of synovial and serological 34 
tests2.  35 
Due to the lack of an absolute test, the Musculoskeletal Infection Society (MSIS) introduced a 36 
set of diagnostic criteria for PJI that were recently modified by the International Consensus on 37 
Periprosthetic Joint Infection (ICM)3. The latter includes major and minor diagnostic criteria. 38 
The minor criteria include the measure of synovial fluid white blood cell count, neutrophil 39 
differential, culture, and leukocyte esterase testing (Table 1). Although numerous serum markers 40 
for PJI have been evaluated in the past including interlukin-6 (IL-6) and others 1, the most widely 41 
used serums tests for diagnosis of PJI are erythrocyte sedimentation rate(ESR) and C-reactive 42 
protein(CRP)2. With the exception of a recent synovial biomarker, namely alpha defensin, none 43 
of the tests being used to diagnose PJI were developed for that purpose and their optimal 44 
threshold for diagnosis of PJI remains unknown.3 45 
Moreover, the levels of ESR and CRP may be normal in patients with PJI caused by slow 46 
growing organisms such as Proprionibacterium acnes4,5. In fact the document introducing the 47 
MSIS criteria for PJI explicitly states that the levels of some of these markers may be normal in 48 
the presence of PJI caused by slow growing organisms that do not elicit physiological 49 
inflammation and cautions clinicians in interpreting the level of serological markers in these 50 
situations 6.  51 
Recently, synovial fluid biomarkers have been shown to be useful in reaching or refuting the 52 
diagnosis of PJI. Synovial fluid alpha defensin, when combined with synovial CRP, has 53 
5 
demonstrated a sensitivity of 97% and specificity of 100% for the diagnosis of PJI.7 There are, 54 
however, many issues with the use of synovial biomarkers for the diagnosis of PJI. Obtaining 55 
synovial fluid is invasive and painful to patients. There are not infrequent occasions when either 56 
inadequate amount of fluid is available to perform all tests or worse, no fluid is retrieved from 57 
the joint. In addition there is a theoretical, yet real, concern for the introduction of infection into 58 
the joint 8 and in difficult aspirations, especially the hip, contamination of the aspirated fluid may 59 
occur leading to false positive results 9. 60 
Another challenge relates to the lack of a reliable and easily accessible test that can help 61 
determine the optimal timing of reimplantation. ESR and CRP are not reliable markers in this 62 
situation as their level is often elevated in the postoperative period 3,10. Two independent studies 63 
have demonstrated that the level of ESR and CRP at the time of reimplantation is not predictive 64 
of treatment failure11,12. 65 
The aforementioned issues highlight the need for a reliable serum test that can help diagnose PJI 66 
and possibly determine the optimal timing of reimplantation. We have been in search of such a 67 
test over the past few years.  Through a grant bestowed to us by the ***Blinded by JBJS***, we 68 
have evaluated over 30 serum and synovial markers for this purpose including D-dimer.  69 
Numerous studies have shown that systemic and local infections result in fibrinolytic activities13–70 
15. D-dimer has been traditionally used as a screening test for detecting deep venous thrombosis 71 
(DVT) but largely abandoned because of its poor performance. More recently, serum D-dimer 72 
has gained attention for its role in predicting poor outcome in sepsis and bacteremia16,17. An in 73 
vivo study on foals with septic arthritis also demonstrated a marked elevation in the level of 74 
synovial fluid D-dimer in these animals14.  75 
6 
We hypothesized that patients with PJI may have high levels of circulating D-dimer, and that the 76 
presence of high levels of D-dimer may be indicative of persistent infection in patients awaiting 77 
reimplantation. 78 
 79 
MATERIALS AND METHODS: 80 
Upon institutional review board approval, patients who underwent total joint arthroplasty (TJA) 81 
were prospectively enrolled in this study from April 2015 to August 2016. Patients undergoing 82 
primary and revision arthroplasty were included except those with any type of skin ulcer, 83 
hematoma, recent trauma or dislocation (within two weeks), visible ecchymosis, prosthetic heart 84 
valves, and those with a history of hypercoagulation disorders. The patients enrolled in this study 85 
fall under five categories: those undergoing primary total joint arthroplasty (group A), revision 86 
arthroplasty due to aseptic failure (group B), patients undergoing resection arthroplasty and 87 
spacer insertion for the treatment of PJI (group C), patients with treated PJI undergoing 88 
reimplantation surgery (reimplantation) (group D), and finally patients with known infection in a 89 
site other than a joint (group E). None of the patients in groups A-D were thought to have 90 
concurrent infections. 91 
Sex, age, joint, and comorbid conditions including systemic inflammatory disease such as 92 
rheumatoid arthritis, systemic lupus erythrematosus, psoriasis, polymyalgia rheumatica, 93 
sarcoidosis, inflammatory bowel disease, gout, hepatitis B and C, lymphocytic leukemia, 94 
myelodysplastic syndrome, multiple myeloma were recorded. Moreover concurrent antibiotic 95 
treatment (not including a single dose of prophylactic perioperative antibiotic), and isolated 96 
organisms were noted for all the patients. A venous blood sample was obtained preoperatively on 97 
the day of surgery and analyzed for serum D-dimer, erythrocyte sedimentation rate (ESR), and 98 
7 
C-reactive protein (CRP). PJI was defined using the MSIS criteria18 (Table 1). As part of the 99 
standard protocol at our institution, surgeons obtain at least three intraoperative tissue culture 100 
specimens from patients undergoing revision arthroplasty. Cultures are then incubated for up to 101 
fourteen days. Furthermore, when a pre-operative synovial fluid aspiration is performed, cell 102 
count, neutrophil differential and cultures are requested.  103 
Our cohort consists of 245 patients; primary arthroplasty (N=23), aseptic revisions (N=86), 104 
revisions for PJI (N=57), reimplantations (N=29), and those that were clinically diagnosed with 105 
infection in areas other than a joint (N=50), that included 34 cases of urinary tract infections, 9 106 
cases of pneumonia, and 5 cases of upper respiratory infections. Eleven patients were excluded 107 
that included history of trauma within 14 days of the surgery (3 patients), revision for dislocation 108 
(3 patients), presence of extensive ecchymosis (2 patients), presence of prosthetic cardiac valve 109 
(1 patient), and history of deep venous thrombosis (1 patient), and presence of skin ulcer on hand 110 
(1 patient) (Figure 1). Patient demographics are presented in table 2. 111 
Patients were followed closely for a minimum of 6 months, the nature of complications and 112 
reason for readmission or reoperation were recorded.  113 
 114 
Statistical Analysis 115 
Descriptive statistics were used to report all the laboratory values. The results of the diagnostic 116 
tests were compared between the groups using Mann-Whitney test considering a p-value<0.005 117 
as a significance of difference between the groups. The optimal threshold for D-dimer as a 118 
diagnostic test for PJI was determined by Youden’s J statistic (J = Sensitivity + Specificity – 1) 119 
based on its correspondence with the diagnosis. The sensitivity and specificity of the diagnostic 120 
8 
tests were calculated along with their 95% confidence intervals. All statistical analyses were 121 
performed using GraphPad Prism, version 7.0a, GraphPad software Inc. California, USA. 122 
Source of Funding: This study was funded in part by a grant from the Orthopaedic Research and 123 
Education Foundation (OREF).  124 
 125 
RESULTS: 126 
Serum D-dimer was significantly higher in patients with PJI; median D-dimer was 1,110 ng/mL 127 
(range: 243-8,487 ng/mL) in patients with PJI versus 299 ng/mL (range: 106-2,571 ng/mL) in 128 
patients without infection undergoing aseptic revision (p-value<0.0001). The mean D-dimer was 129 
212.5 ng/mL (range: 150-430 ng/mL) in the primary arthroplasty cohort, 399.9 ng/mL (range: 130 
106-2,571 ng/mL) in the aseptic revision arthroplasty cohort, 1,634 ng/mL (range: 243-8,487 131 
ng/mL) in PJI patients, 806.7 ng/mL (range: 170-6,381 ng/mL) in the reimplantation group, and 132 
451 ng/mL (range: 150-1,420 ng/mL) in patients with infection in sites other than a joint (Figure 133 
2).   134 
The median ESR and CRP were also significantly higher in patients with PJI; the median ESR 135 
was 46 mm/hr (range, 7 to 127 mm/hr) in patients with PJI undergoing resection compared to 15 136 
mm/hr (range, 1 to 89 mm/hr) in patients undergoing revision due to aseptic failure (p<0.0001) 137 
and for CRP the median was 37 mg/L (range, 2 to 328 mg/L) in the PJI group vs. 3 mg/L (range, 138 
1 to 81 mg/L) in the non-infected cases (p<0.0001). The mean ESR was 15.3 mm/hr (1-36 139 
mm/hr) in the primary arthroplasty cohort, 19.2 mm/hr (2-89 mm/hr) in the aseptic revision 140 
arthroplasty cohort, 75.2 mm/hr (7-120 mm/hr) in PJI patients (patients who underwent revision 141 
arthroplasty due to infection), 32.4 mm/hr (4-69 mm/hr) in the reimplantation group, and 72 (35-142 
121 mm/hr) in patients with infection in sites other than a joint (Figure 3). The mean CRP was 143 
9 
4.2 mg/L (1-20 mg/L) in the primary group, 8.2 mg/L (1-81 mg/L) in aseptic revisions, 56 mg/L 144 
(2-328 mg/L) in PJI patients, 9.2 mg/L (1-27 mg/L) in the reimplantation group, and 47 mg/L (1-145 
179 mg/L) in patients with infection in sites other than a joint (Figure 4), (Table 3).  146 
 147 
Using the MSIS thresholds (Table 1), serum CRP and ESR had a sensitivity of 79% (95% 148 
Confidence interval [CI]: 66-88%) and 74% (95% CI: 60-84%) and a specificity of 80% (95% 149 
CI: 72-86%) and 78% (95% CI: 70-85%), respectively. The sensitivity and specificity of ESR 150 
and CRP combined was 84% (95% CI: 76-90%) and 47% (95% CI: 36-58%), respectively. 151 
Using the calculated threshold for D-dimer (850 ng/mL), Serum D-dimer test had a better 152 
sensitivity at 89% (95% CI: 77-95%) and a better specificity at 93% (95% CI: 86-96%) for 153 
diagnosing PJI (Table 4). D-dimer was also useful in predicting the presence of infection at the 154 
time of reimplantation. Five patients had elevated D-dimer at the time of reimplantation. Of these 155 
patients who were reimplanted, two had a positive culture (Propionibacterium acnes in one and 156 
Staphylococcus epidermidis in the other one) from intraoperative specimens (Patients #9 and #14 157 
in Table 5). Both of these patients subsequently failed due to infection. It is interesting to note 158 
that the corresponding CRP and ESR levels were falsely negative in both of these patients (CRP: 159 
8 and 1 mg/L and ESR: 20 and 9 mm/hr). We are closely following the other three patients with 160 
“false positive” D-dimer at the time of reimplantation. 161 
Seventeen patients in our cohort required reoperations (Table 5). 15 patients underwent revision 162 
surgery for infection; of which, 10 patients subsequently were reimplanted. Among these 10 163 
patients, D-dimer decreased below its threshold level in 7 patients at the time of reimplantation. 164 
The culture results of the PJI patients are provided in table 6. The rate of culture negative PJI in 165 
the cohort was 33% (19/57). The false negative rate for D-dimer in this subgroup was 5% (1/19) 166 
10 
whereas it was 47% (9/19) for CRP and 52% (10/19) for ESR (Table 7). The data relating to 167 
patients with infection in sites other than a joint was very interesting. All 50 patients (100%) had 168 
elevated ESR (>30 mm/hr), 42 patients (84%) had elevated CRP (>10 mg/L), and the D-dimer 169 
was elevated above 850 ng/dL in 6 patients (12%).  170 
 171 
DISCUSSION: 172 
This is, to our knowledge, the first study that evaluates the role of serum D-dimer as a diagnostic 173 
test for PJI and predicting the presence of infection in patients awaiting reimplantation. In the 174 
given cohort that we assembled over the past two years, D-dimer was more accurate than ESR 175 
and CRP, even when combined, in diagnosing PJI and also predicting the presence of infection at 176 
the time of reimplantation. Out of five patients with “elevated” D-dimer at the time of 177 
reimplantation, two patients had a positive culture from the samples taken during reimplantation. 178 
ESR and CRP were both normal in these two patients. Both of these patients subsequently failed 179 
due to infection. Thus, we believe that the sensitivity and specificity of D-dimer is likely higher 180 
than calculated in this cohort as some of the patients with “positive” D-dimer who were 181 
classified as non-infected, may indeed have infection by slow growing organisms that did not 182 
elicit physiological inflammation and failed to meet the MSIS criteria for PJI. The MSIS 183 
workgroup proposing the PJI definition cautioned clinicians about such a possibility, when 184 
organisms like P. acnes causing PJI may not elicit adequate inflammation and all minor criteria 185 
may be negative 19,20.  Thus, using the MSIS criteria for these patients may have adversely 186 
affected the performance of D-dimer. 187 
Clinicians are familiar with serum D-dimer as it has been used, albeit with disappointing 188 
performance, in screening patients for venous thromboembolism (VTE).  21–23 In recent years 189 
11 
evidence has been emerging to suggest that the D-dimer levels are likely to rise in the setting of 190 
systemic inflammation and infection, especially in a joint. 14,16,17. Busso et al. 24 explained how 191 
D-dimer levels are elevated in patients with rheumatoid arthritis. Inflamed synovium secrets a 192 
significant amount of fibrin and degradation of these proteins subsequently leads to an increased 193 
concentration of serum and synovial fluid D-dimer.24 Studies have also shown that coagulation 194 
factors that are formed following activation of the coagulation cascade can have 195 
proinflammatory effects. 25,26 Inducible tissue factor expression has been reported in endothelial 196 
cells and monocytes following in vitro augmentation with proinflammatory factors, such as 197 
cytokines (IL-1, IL-6, and tumor necrosis factor [TNF]). 27 Furthermore, several studies have 198 
shown that fibrin(ogen) itself can mediate and enhance the inflammatory response 28–30. In fact 199 
an older study by Ribera et al.14 demonstrated that the concentration of synovial fluid D-dimer 200 
increased several folds in foals with septic joint disease, endorsing the fact that D-dimer is 201 
involved in mediating inflammation/infection in the joint. The increased fibrinolytic activity and 202 
generation of byproducts such as D-dimer are believed to localize the infecting organisms or 203 
inflammatory cells and thus prevent their systemic damage. The byproduct of this fibrinolytic 204 
activity also “leaks” into the circulation and can thus be measured.   205 
Serum D-dimer levels has been shown to be a significant prognostic factor in patients with 206 
systemic sepsis. Rodelo et al. 31 reported that higher levels of D-dimer are associated with an 207 
increased 28-day mortality in patients with sepsis and emphasized the prognostic role of D-dimer 208 
for septic patients.   209 
This study has several strengths. First, patients were recruited prospectively and unlike most 210 
diagnostic studies that limit their population to patients without concurrent inflammatory 211 
conditions, our cohort was heterogeneous and included patients with inflammatory conditions, 212 
12 
metallosis, polyethylene wear, as well as those who were receiving ongoing antibiotic therapy. 213 
We believe that the inclusion of these patients provided a more realistic clinical situation 214 
allowing for the evaluation of D-dimer in clinical settings. As part of our ongoing efforts, we 215 
investigated numerous other serum biomarkers in an animal model of PJI and also in a small 216 
cohort of patients and found that D-dimer outperformed all of the other serum markers of 217 
infection1. The second strength of this study is that we included a cohort of “positive control” 218 
patients with infection at sites other than a joint. This allowed us to assess whether D-dimer is 219 
elevated by non-joint related infections. It certainly appeared that D-dimer is a better test than 220 
ESR and CRP in this clinical setting as it was elevated in only 12% of patients compared to ESR 221 
being elevated in 100% and CRP being elevated in 84% of patients. The other strength of this 222 
study is that it evaluated the role of a serum marker for patients undergoing reimplantation, 223 
arguably the most understudied area in orthopedic infections. D-dimer appeared to have an 224 
impressive performance in that setting also. Finally, we used statistical methods to determine the 225 
appropriate threshold for D-dimer for diagnosis of PJI. Although the latter could change with 226 
addition of further data from our institution or others, it is a great starting point and a guide to 227 
clinicians who may wish to use this test.  228 
The study suffers some limitations and our findings should be interpreted in light of these 229 
shortcomings. There is no “gold standard” for the diagnosis of PJI, therefore, some of the 230 
patients that were allocated in the non-infection group might be in fact, infected and the reverse 231 
may also be true. The MSIS criteria for PJI, however, is universally accepted as the best 232 
definition for PJI 3 and was used as the gold standard in this study and the analyses that were 233 
performed. Although patients with systemic inflammatory diseases and those who received 234 
immunosuppressive therapies were not excluded from this study, our cohort contains a few 235 
13 
patients with these conditions. In the absence of a large number of patients, we refrain from 236 
making comments regarding the value of D-dimer in evaluating patients for PJI who have 237 
concurrent inflammatory joint disease. We are, in a follow-up study, examining this issue. 238 
Lastly, the lack of frozen section in these patients may be considered as a shortcoming. We do 239 
not routinely perform frozen section or histology in our patients undergoing revision surgery or 240 
reimplantation due to the fact that we believe the latter, at least at our institution, has serious 241 
limitations. Therefore, data related to frozen section or histology was not available for the 242 
comparisons that were performed in this study.  243 
This study, for the first time, demonstrates the real value of serum D-dimer for diagnosis of PJI 244 
and in determining the presence of infection in patients undergoing reimplantation. Based on the 245 
findings of this study, we believe that serum D-dimer, an inexpensive and universally available 246 
test, should be added to the work-up of patients for PJI. Elevated D-dimer for patients 247 
undergoing reimplantation should be taken seriously as it could be an indication of persistent 248 
infection.  249 
14 
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Figure Legend:  342 
Figure 1.  Number of included and excluded patients in each study group. 343 
Figure 2. D-dimer levels in the study groups. The red line determines the calculated threshold 344 
for diagnosis of PJI (850 ng/mL). Group A: Primary arthroplasties, Group B: Aseptic revisions, 345 
Group C: Revisions for infection, Group D: Reimplantations, and Group E: Patients with 346 
infection in sites other than a joint. One of the patients in Group C had a D-dimer of 8,487 347 
ng/mL that is not represented in the graph. 348 
 349 
Figure 3. ESR levels in the study groups. The red line determines the threshold recommended by 350 
the musculoskeletal infection society (30 mm/hr). Group A: Primary arthroplasties, Group B: 351 
Aseptic revisions, Group C: Revisions for infection, Group D: Reimplantations, and Group E: 352 
Patients with infection in sites other than a joint. 353 
 354 
Figure 4. CRP levels in the study groups. The red line determines the threshold recommended 355 
by the musculoskeletal infection society (10 mg/L). Group A: Primary arthroplasties, Group B: 356 
Aseptic revisions, Group C: Revisions for infection, Group D: Reimplantations, and Group E: 357 
Patients with infection in sites other than a joint. 358 
  359 
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Table 1. Definition of PJI according to the musculoskeletal infection society and the threshold 360 
for the minor diagnostic criteria. 361 
 362 
PJI is present when one of the major criteria or three out of five minor criteria exist 
Major Criteria 1) Two positive periprosthetic cultures with phenotypically 
identical microorganism OR 
2) A sinus tract communicating with the joint  
Minor Criteria 
 
Recommended Threshold  





2) Elevated SF WBC count  
OR 




+ Or ++ 
3) Elevated SF PMN% 80% 
4) Positive histological 
analysis of the 
periprosthetic tissue 
>5 neutrophil per high power 
field in 5 high power fields 
(×400) 
5) A single positive culture  
 363 
  364 
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Table 2. Demographics of the study groups. Group A: Primary arthroplasty, Group B: Aseptic 365 
revisions, Group C: First stage of a two stage exchange revision protocol, Group D: Second stage 366 
of a two stage exchange protocol (reimplantation), Group E: Patients with infections other than 367 
periprosthetic joint infection. 368 
 369 
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Table 3. Comparing laboratory values between two cohorts of patients with infection either 372 








*Laboratory values are presented as median and (range).  381 
  382 
Table 3.  
 Patients with 
periprosthetic joint 
infection (Group C) 
(N=57) 
Patients with 
infection in sites 








46 (7 to 127) 67 (35 to 121) 0.0016 
C-reactive protein 
(mg/L)* 
37 (2 to 328) 42 (1 to 79) 0.9732 
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Table 4. Performance of the serum tests for diagnosing periprosthetic joint infection. ESR: 383 
Erythrocyte Sedimentation Rate, CRP: C-reactive Protein. 384 
 385 
 ESR CRP D-Dimer 
TN 110 112 128 
FN 15 12 6 
FP 30 28 10 
TP 42 45 51 
Sensitivity 73.68% 78.95% 89.47% 
SE of  
Sensitivity 
5.83% 5.40% 4.06% 
Specificity 78.57% 80.00% 92.75% 
SE of 
Specificity 
3.47% 3.38% 2.21% 
PPV 58.33% 61.64% 83.61% 
SE of PPV 5.81% 5.69% 4.74% 
NPV 88.00% 90.32% 95.52% 
SE of NPV 2.91% 2.66% 1.79% 
+LR 3.43 3.94 12.34 
-LR 0.33 0.26 0.11 
 386 
TN: True Negative, FN: False Negative, FP: False positive, TP: True Positive, SE: Standard 387 
Error, PPV: Positive Predictive Value, NPV: Negative Predictive Value, +LR: Positive 388 
Likelihood Ratio, -LR: Negative Likelihood Ratio 389 
  390 
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Table 5. Patients that required reoperation in our study cohort. N/A: not available.  
Name Date of Procedure Primary Aseptic Revision Revision for PJI Reimplantation CRP (mg/L) ESR (mm/Hr) D-dimer (ng/mL) Intraoperative Cultures 
Patient #1 
8/19/2015   X  145 120 3,051 MSSA 
4/8/2016   X  16 40 3,664 MSSA 
6/22/2016    X 9 69 170 NEGATIVE 
Patient #2 
1/27/2016   X  179 105 959 STAPHYLOCOCCUS AUREUS 
4/22/2016    X 6 18 579 NEGATIVE 
Patient #3 
4/24/2016   X  328 83 978 MSSA 
7/18/2016    X 20 29 762 NEGATIVE 
Patient #4 
2/9/2016   X  21 33 2,536 STAPHYLOCOCCUS EPIDERMIDIS 
4/12/2016   X  4 22 973 NEGATIVE 
Patient #5 
4/27/2016   X  122 1270 930 MSSA 
7/13/2016    X 11 14 548 NEGATIVE 
Patient #6 
3/30/2016   X  43 60 1,228 STAPHYLOCOCCUS EPIDERMIDIS 
5/25/2016   X  77 47 1,502 MSSA 
Patient #7 
5/31/2016   X  3 14 910 NEGATIVE 
7/19/2016    X 7 29 637 NEGATIVE 
Patient #8 
6/6/2016  X   14 44 298 N/A 
6/28/2016   X  137 89 776 MSSA 
Patient #9 
2/2/2016   X  25 60 1,101 STAPHYLOCOCCUS EPIDERMIDIS 
4/12/2016    X 8 20 1,038 STAPHYLOCOCCUS EPIDERMIDIS 
Patient #10 
3/25/2016   X  26 34 2,060 GROUP B STREPTOCOCCUS 
6/17/2016    X 6 12 614 NEGATIVE 
Patient #11 
5/26/2015   X  8 7 1,110 P.ACNES 
3/22/2016   X  35 73 928 NEGATIVE 
Patient #12 
4/27/2015 X    1 11 271 N/A 
3/14/2016  X   1 13 311 N/A 
Patient #13 
3/1/2016   X  65 36 2,038 NEGATIVE 
5/27/2016    X 11 27 2,113 NEGATIVE 
Patient #14 
10/23/2015   X  109 48 8,487 STREP SANGUINIS 
3/11/2016    X 1 9 6,381 P.ACNES 
Patient #15 
3/23/2016   X  127 86 1,483 MSSA 
6/10/2016    X 6 30 877 NEGATIVE 
Patient #16 
6/3/2015   X  47 69 995 NEGATIVE 
6/29/2016   X  37 45 1,391 MRSA 
Patient #17 
6/7/2016    X 4 47 204 NEGATIVE 
7/26/2016   X  34 120 521 SERRATIA MARCESCENS 
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Culture results Count 
Methicillin-sensitive Staphylococcus aureus 12 
Staphylococcus epidermidis 9 
Methicillin-resistant Staphylococcus aureus  4 
Propionibacterium acnes 3 
Streptococcus agalactiae Group B 2 
Polymicrobial 2 
Anaerobic gram positive cocci 1 
Klebsiella pneumoniae 1 
Streptococcus sanguinis 1 
Enterobacter cloacae 1 
Streptococcus mutans 1 
Serratia marcescens 1 
Negative Cultures 19 
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Table 7. Periprosthetic joint infections with negative culture. The false-negative laboratory values are 
marked in yellow (Thresholds are based on the Musculoskeletal Infection Society diagnostic criteria 










1 57 80 911 
2 37 13 1906 
3 32 13 2166 
4 10 29 1106 
5 89 94 2577 
6 78 93 2258 
7 5 25 999 
8 65 36 2038 
9 6 21 929 
10 35 73 928 
11 4 22 973 
12 8 10 923 
13 13 66 2631 
14 8 17 770 
15 3 14 910 
16 31 36 1265 
17 2 10 243 
18 2 31 4733 











































Figure 4.  
